Investment

Botanix Pharmaceuticals Secures $40 Million to Accelerate Sofdra Rollout

Botanix Pharmaceuticals Ltd (ASX: BOT) is a commercial dermatology company based in Philadelphia and Phoenix, specialising in innovative treatments for skin conditions. The company has many prospective products in their development pipeline including Sofdra, BTX 1503 for moderate to severe acne currently pending Phase 3 study; BTX 1702 for rosacea which has seen positive Phase […]

16th April 2025
Investment

Botanix Raises $40M to Accelerate U.S. Rollout of Hyperhidrosis Treatment Sofdra™

15th April 2025

REACH YOUR FULL POTENTIAL

Ready to elevate yourgame to new heights? Look no further!

By submitting your details below, you’ll gain exclusive access to the finest content in investment and lifestyle from KODARI Magazine. Whether you’re seeking insights into luxury living, expert investment insights, or the latest trends in high-end fashion and travel, we’ve got you covered.